Yujia Li

Articles by Yujia Li

100 Imlunestrant Plus Abemaciclib Versus Fulvestrant Plus Abemaciclib in Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2–) Advanced Breast Cancer (ABC): An Indirect Treatment Comparison (ITC) of Three Phase 3 Trials

ByKomal L. Jhaveri,Francois Clement Bidard,Kevin Kalinsky, MD, MS,Patrick Neven, MD, PhD,Hope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Lacey Litchfield,Christoph Cramer von Laue,Sory Traore,Francisco Sapunar,Yujia Li,Joyce O’Shaughnessy, MD

May 21st 2026

Latest Updated Articles

Trending on CancerNetwork

Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis

Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization

Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer

Can an All-Oral HMA Regimen Change Frontline Care in Unfit AML?

FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer